



Lighting the way
to *clear* skin.

Model. Not actual patient.

Join the acne treatment *revolution*.

Welcome patients to a new era of clear skin with AviClear, the first and original FDA-cleared energy device for the treatment of mild, moderate, and severe acne.*

AviClear uses a 1726 nm wavelength to suppress sebocytes and eliminate acne in three quick treatment sessions, without any downtime.^{1†}



Long-lasting, durable results²



Safe for all skin types, tones and severities in both adolescents and adults¹



Three quick 30-minute treatment sessions, without downtime¹



No labs or iPLEDGE requirements[‡]




High patient satisfaction²


Treat acne at the *source*.

Research indicates that at 1726 nm, pure sebum absorbs approximately 2x more energy compared to H₂O.³


AviClear selectively delivers energy to damage the sebocytes and suppress sebum production without compromising the epidermis.



The proven 1726 nm wavelength selectively delivers energy to the sebaceous gland.



The heat damages the sebocytes and suppresses sebum production, while other chromophores and the epidermis remain intact.



AviClear[™]
CUTERA®

The demand is *clear*.

Not only does AviClear meet the demand for the #1 dermatologic condition, but it's also a lasting, durable solution for mild, moderate, and severe acne.^{2,4}

\$4.27B

estimated U.S. acne treatment market size in 2021.⁵

48%

of patients are unsatisfied with their current acne treatment.⁶

AviCool[™]

AviClear is designed with the exclusive AviCool. The combination of sapphire contact cooling and smart sensors provides a safe and comfortable treatment experience.^{2†}

Patients have described the sensation of AviClear treatments like a "light snapping against the skin."

The median score of treatment comfortability was five out of ten.¹



The results are *clear*.

AviClear provides results, even for severe acne cases.

87%

of patients had a $\geq 50\%$ reduction in inflammatory lesions at six months after the final treatment session (up from 80% at three months).^{1§}

Moderate and severe acne patients had a reduction of

93%

in mean nodule count at six months after the final treatment session.¹

2 out of 3

patients were assessed as clear or almost clear 12 months after their final treatment session.¹

97%

reduction in inflammatory lesion count at two years.²



A program that puts your practice *first*.

Introducing Avi360

A comprehensive approach that connects you with resources to support practice growth. It starts with a dedicated concierge team.

One number. One email. One voice.



The Cutera Concierge team is the point of contact for AviClear support throughout the partnership.

Lasting results. So future acne *never* sees the light of day.

AGE: 25 | SKIN TYPE: II | SEVERITY: Improves from Severe to Mild



BASELINE

3 MONTHS AFTER FINAL TREATMENT SESSION

6 MONTHS AFTER FINAL TREATMENT SESSION

AGE: 18 | SKIN TYPE: V | SEVERITY: Improves from Moderate to Clear



BASELINE

6 MONTHS AFTER FINAL TREATMENT SESSION

12 MONTHS AFTER FINAL TREATMENT SESSION

AGE: 18 | SKIN TYPE: IV | SEVERITY: Improves from Severe to Clear



BASELINE

6 MONTHS AFTER FINAL TREATMENT SESSION

12 MONTHS AFTER FINAL TREATMENT SESSION

AGE: 17 | SKIN TYPE: IV | SEVERITY: Improves from Moderate to Clear



BASELINE

6 MONTHS AFTER FINAL TREATMENT SESSION

12 MONTHS AFTER FINAL TREATMENT SESSION

AGE: 23 | SKIN TYPE: IV | SEVERITY: Improves from Moderate to Almost Clear



BASELINE

6 MONTHS AFTER FINAL TREATMENT SESSION

12 MONTHS AFTER FINAL TREATMENT SESSION

AGE: 25 | SKIN TYPE: III | SEVERITY: Improves from Moderate to Almost Clear



BASELINE

6 MONTHS AFTER FINAL TREATMENT SESSION

2 YEARS AFTER FINAL TREATMENT SESSION

Technical specifications

Wavelength	1726 nm
Power	100 W
Fluence	Up to 30 J/cm ²
Pulse duration	Up to 50 ms
Spot size (Area)	3.0 mm (0.07 cm ²)
Treatment scan patterns	Single Spot; Hexagonal Array
Cooling	0° C to 5° C
Console dimensions	24.5 x 19 x 38 in. (0.62 x 0.48 x 0.97 m)
Console weight	125 lbs. (56.7 kg)



Become a provider today.

Scan for more information.

www.aviclear.com

CUTERA®

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients.

For more information, call **1-415-657-5500** or **1-888-4CUTERA** or visit www.cutera.com.

*AviClear is also Health Canada approved for acne scars.

†Comfort level varies by tolerance. There were no instances of dropout reported in the clinical trials.

‡For U.S. acne patients opting for isotretinoin treatment only.

§Treatment success was defined as a reduction in inflammatory lesions of greater than or equal to 50%.

References: **1.** Data on file. FDA clearance study. Cutera, Inc. **2.** Goldberg D, et al. Selective photothermolysis with a novel 1726 nm laser beam: A safe and effective solution for acne vulgaris. *J Cosmet Dermatol.* 2022;Dec 28. Online ahead of print. **3.** Sakamoto FH, et al. Selective photothermolysis to target sebaceous glands: theoretical estimation of parameters and preliminary results using a free electron laser. *Lasers SurgMed.* 2012 Feb;44(2):175-83. **4.** American Academy of Dermatology. Skin conditions by the numbers. Available from <https://www.aad.org/media/stats-numbers>. Accessed Feb. 6, 2023. **5.** Fortune Business Insights. The U.S. acne treatment market is projected to grow from \$4.50 billion in 2022 to \$6.12 billion by 2029, at a CAGR of 4.5% in forecast period, 2022-2029. Available from <https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-106565>. Accessed Mar. 16, 2023. **6.** Hayran Y et al. Factors of affecting adherence and patient satisfaction of treatment: a cross sectional study of 500 patients with acne vulgaris. *J Dermatol Treat.* 2021; 32 (1):64-69.

CELEBRATING **25** YEARS
OF CUTERA